Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

Stopped The study was terminated prematurely for logistic reasons, not related to safety or efficacy of the vaccine.

Conditions

• Influenza

Interventions

• BIOLOGICAL: GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
• BIOLOGICAL: Infanrix™-IPV/Hib
• BIOLOGICAL: Prevenar

Sponsor

GlaxoSmithKline